

CHAPTER ONE

Adrenergics and Adrenergic-Blocking Agents

ROBERT K. GRIFFITH
School of Pharmacy
West Virginia University
Morgantown, West Virginia

Contents

1	Introduction, 2
2	Clinical Applications, 2
2.1	Current Drugs, 2
2.1.1	Applications of General Adrenergic Agonists, 9
2.1.2	Applications of α_1 -Agonists, 12
2.1.3	Applications of α_2 -Agonists, 13
2.1.4	Applications of β -Agonists, 14
2.1.5	Applications of Antidiuretics, 14
2.1.6	Applications of Nonselective α -Antagonists, 15
2.1.7	Applications of Selective α_1 -Antagonists, 15
2.1.8	Applications of β -Antagonists, 16
2.1.9	Applications of α/β -Antagonists, 16
2.1.10	Applications of Agonists/Antagonists, 16
2.2	Absorption, Distribution, Metabolism, and Elimination, 16
2.2.1	Metabolism of Representative Phenylethylamines, 16
2.2.2	Metabolism of Representative Imidazolines and Guanidines, 18
2.2.3	Metabolism of Representative Quinazolines, 19
2.2.4	Metabolism of Representative Aryloxypropanolamines, 19
3	Physiology and Pharmacology, 21
3.1	Physiological Significance, 21
3.2	Biosynthesis, Storage, and Release of Norepinephrine, 22
3.3	Effector Mechanisms of Adrenergic Receptors, 25
3.4	Characterization of Adrenergic Receptor Subtypes, 25
4	History, 26


Burger's Medicinal Chemistry and Drug Discovery
Sixth Edition, Volume 6: Nervous System Agents
Edited by Donald J. Abraham
ISBN 0-471-27401-1 © 2003 John Wiley & Sons, Inc.

5 Structure-Activity Relationships, 28
5.1 Phenylethylamine Agonists, 28
5.1.1 R ¹ Substitution on the Amino Nitrogen, 28
5.1.2 R ² Substitution α to the Basic Nitrogen, Carbon-2, 28
5.1.3 R ³ Substitution on Carbon-1, 29
5.1.4 R ⁴ Substitution on the Aromatic Ring, 29

5.1.5 Imidazolines and Guanidines, 30
5.1.6 Quinazolines, 31
5.1.7 Aryloxypropanolamines, 32
6 Recent Developments, 33
6.1 Selective α_{1A} -Adrenoceptor Antagonists, 33
6.2 Selective β_3 -Agonists, 34

1 INTRODUCTION

In both their chemical structures and biological activities, adrenergics and adrenergic-blocking agents constitute an extremely varied group of drugs whose clinical utility includes prescription drugs to treat life-threatening conditions such as asthma and hypertension as well as nonprescription medications for minor ailments such as the common cold. This extensive group of drugs includes synthetic agents as well as chemicals derived from natural products that have been used in traditional medicines for centuries. Many adrenergic drugs are among the most commonly prescribed medications in the United States, including bronchodilators, such as albuterol (**13**) for use in treating asthma, and antihypertensives, such as atenolol (**46**) and doxazosin (**42**). Nonprescription adrenergic drugs include such widely used nasal decongestants as pseudoephedrine (**5**) and naphazoline (**29**). Most of these varied drugs exert their therapeutic effects through action on adrenoceptors, G-protein-coupled cell surface receptors for the neurotransmitter norepinephrine (noreadrenaline, **1**), and the adrenal hormone epinephrine (adrenaline, **2**).



Adrenoceptors are broadly classified into α - and β -receptors, with each group being further

subdivided. Identification of subclasses of adrenoceptors has been greatly aided by the tools of molecular biology and, to date, six distinct α -adrenoceptors (α_{1A} , α_{1B} , α_{1D} , α_{2A} , α_{2B} , α_{2C}), and three distinct β -adrenoceptors (β_1 , β_2 , β_3) have been clearly identified (1), with conflicting evidence for a fourth type of β (β_4) (1–3). In general the most common clinical applications of α_1 -agonists are as vasoconstrictors employed as nasal decongestants and for raising blood pressure in shock; α_2 -agonists are employed as antihypertensives; α_1 -antagonists (α -blockers) are vasodilators and smooth muscle relaxants employed as antihypertensives and for treating prostatic hyperplasia; β -antagonists (β -blockers) are employed as antihypertensives and for treating cardiac arrhythmias; and β -agonists are employed as bronchodilators. The most novel recent advances in adrenergic drug research have been directed toward development of selective β_3 -agonists that have potential applications in treatment of diabetes and obesity (4–8).

2 CLINICAL APPLICATIONS

2.1 Current Drugs

U.S. Food and Drug Administration (FDA)-approved adrenergic and antiadrenergic drugs currently available in the United States are summarized in Table 1.1, which is organized in general according to pharmacological mechanisms of action and alphabetically within those mechanistic classes. Structures of the currently employed drugs are given in Tables 1.2–1.6 according to chemical class. Drugs in a given mechanistic class often have more than one therapeutic application, and may or may not all be structurally similar. Furthermore, drugs from several different mechanistic classes may be employed in a given therapeu-

Table 1.1 Adrenergic and Antiaudrenergic Pharmaceuticals

Class and Generic Name	Trade Name ^a	Originator	Chemical Class	Dose ^{bc}
General agonists				
Amphetamine (3)	Adderall, Dexedrine	SmithKline & French	Phenylethylamine	5–60 mg/day
Dipivefrin (4)	Propine	Klinge	Phenylethylamine	1 drop 2 × daily 0.1% soln.
Ephedrine <i>erythro</i> -(5)	various		Phenylethylamine	50–150 mg/day for asthma
Epinephrine (2)	Adrenaline	Parke-Davis	Phenylethylamine	10–25 mg i.v. for hypotension
				0.3–1.5 mg s.c.
				2–10 µg/min i.v.
				160–250 µg inh.
Mephentermine (6)	Wyamine	Wyeth	Phenylethylamine	30–45 mg, i.m.
Norepinephrine (1)	Levophed	Sterling	Phenylethylamine	0.5–30 µg/min i.v.
Pseudoecephadrine <i>threo</i> -(5)	Various		Phenylethylamine	60–240 mg/day
α ₁ -Agonists				
Levoradefrin (7)	na	Winthrop	Phenylethylamine	1:20,000 in local anesthetics
Metaraminol (8)	Aramine	Sharpe & Dohme	Phenylethylamine	2–10 mg, i.m.
Methoxamine (9)	Vasoxyl	Burroughs Wellcome	Phenylethylamine	10–20 mg, i.m.
Midodrine (10)	ProAmatine	Oesterreichische Stickstoffwerke	Phenylethylamine	30 mg/day
Naphazoline (29)	Various	Ciba	Imidazoline	1–2 drops 0.05% nasal
Oxymetazoline (30)	Various	Merck	Imidazoline	0.03% ophthalmic
Phenylephrine (11)	Various	F. Stearns & Co.	Phenylethylamine	1–2 drops 0.05% nasal
Tetrahydrozoline (31)	Various	Sahyun	Imidazoline	0.025% ophthalmic
Xylometazoline (32)	Ciba	Ciba	Imidazoline	1–3 drops
α ₂ -Agonists				
Apraclonidine (33)	Iopidine	Alcon	Aminoinimidazoline	0.25–0.5% soln. nasal
Brimonidine (34)	Alphagan	Pfizer	Aminoinimidazoline	0.1–0.5 mg i.v. for shock
Clonidine (35)	Catapress	Boehringer	Aminoinimidazoline	1–2 drops of 0.05% soln.
Guanabenz (36)	Wytensin	Sandoz	Arylguanidine	2–3 drops of 0.1% soln.
Guanfacine (37)	Tenex	Wander	Arylguanidine	1–3 mg/day
Methyl)dopa (12)	Aldomet	Merck	Aromatic amino acid	500–2000 mg/day

Table 1.1 (*Continued*)

Class and Generic Name	Trade Name ^a	Originator	Chemical Class	Dose ^{b,c}
<i>β</i> -Agonists				
Albuterol (13)	Proventil, Ventolin	Allen & Hanburys	Phenylethylamine	12–32 mg/day p.o. 2.5 mg 3–4× daily, neb.
Bitolterol (14)	Tornalate	Sterling	Phenylethylamine	0.74–2.22 inh.
Formoterol (15)	Foradil	Yamanouchi	Phenylethylamine	12 μ g, 2× daily inh.
Isoetharine (16)	Bronkosol	I.G. Farben	Phenylethylamine	2 mL 0.25% soln. inh.
Isoproterenol (17)	Isuprel	Boehringer	Phenylethylamine	120–262 μ g, 2–6× daily inh.
Levalbuterol (18)	Xopenex	Sepracor	Phenylethylamine	0.5–5.0 μ g/min, i.v.
Metaproterenol (18)	Alupent, Metaprel	Boehringer	Phenylethylamine	0.63–1.25 mg 3× daily neb.
Pirbuterol (19)	Maxair	Pfizer	Pyridylethylamine	60–80 mg/day p.o.
Ritodrine (20)	Yutopar	Philips	Phenylethylamine	1.3–1.95 mg, 6–8× daily, inh.
Salmeterol (21)	Serevent	Glaxo	Phenylethylamine	0.2–0.4 mg 4–6× daily, inh.
Terbutaline (22)	Brethine	Draco	Phenylethylamine	150–350 μ g/min, i.v.
Antidiurenergics				
Guanadrel (38)	Hylorel	Cutter	Guanidine	10–75 mg/day
Guanethidine (39)	Ismelin	Ciba	Guanidine	10–50 mg/day
Reserpine (60)	reserpine	Ciba	Alkaloid	0.05–0.5 mg/day
Metyrosine (23)	Demser	Merck	Aromatic amino acid	1–4 g/day
<i>α</i> -Antagonists				
Dapiprazole (61)	Rev-Eyes	Angelini-Francesco	Piperidinyltriazole	2 drops 0.5% soln.
Phenoxybenzamine (62)	Dibenzyline	SmithKline & French	Haloalkylamine	20–120 mg/day
Phentolamine (40)	Regitine	Ciba	Imidazoline	5–10 mg i.v.
Tolazoline (41)	Priscoline	Ciba	Imidazoline	40–200 mg/day
Selective				
<i>α₁</i> -antagonists				
Doxazosin (42)	Cardura	Pfizer	Quinazoline	1–16 mg/day
Prazosin (43)	Minipress	Pfizer	Quinazoline	1–9 mg/day for BPH
Tamsulosin (24)	Flomax	Yamanouchi	Phenylethylamine	6–20 mg/day for hypertension
Terazosin (44)	Hytrin	Abbott	Quinazoline	0.4–0.8 mg/day
				5–20 mg/day

β -Antagonists				
Acebutirol (45)	Sectral	May & Baker	Aryloxypropanolamine	200–1200 mg/day
Atenolol (46)	Tenormin	ICI	Aryloxypropanolamine	25–150 mg/day
Betaxolol (47)	Betoptic, Kerlone	Synthelabo	Aryloxypropanolamine	Hypertension: 10–20 mg orally Glaucoma: 1–2 drops 0.5% soln. 2× daily
Bisoprolol (48)	Zebeta	Merck	Aryloxypropanolamine	1.25–20 mg/day
Carteolol (49)	Cartrol, Ocupress	Otsuka	Aryloxypropanolamine	2.5–10 mg/day
Esmolol (50)	Brevibloc	American Hospital Supply	Aryloxypropanolamine	50–100 μ g/kg/min
Levobetaxolol S-(–)-(47)	Betaxon	Alcon	Aryloxypropanolamine	1 drop 0.5% soln., 2× daily
Levobunolol (51)	Betagan	Warner-Lambert	Aryloxypropanolamine	1–2 drops 0.5% soln., 1–2× daily
Metipranolol (52)	OptiPranolol	Boehringer	Aryloxypropanolamine	1 drop 0.3% soln., 2× daily
Metoprolol (53)	Lopressor, Toprol-XL	AB Hässle	Aryloxypropanolamine	100–450 mg/day
	Toprol-XL			XL 50–100 mg/day
Nadolol (54)	Corgard	Squibb	Aryloxypropanolamine	40–320 mg/day
Penbutolol (55)	Levatol	Hoechst	Aryloxypropanolamine	20–80 mg/day
Pindolol (56)	Visken	Sandoz	Aryloxypropanolamine	10–60 mg/day
Propranolol (57)	Inderal, Inderal LA	ICI	Aryloxypropanolamine	160–640 mg/day
Sotalol (25)	Betapace	Mead Johnson	Phenylethylamine	160–320 mg/day
Timolol (58)	Timoptic	Frosst	Aryloxypropanolamine	Hypertension: 10–60 mg/day Glaucoma: 1 drop 0.25% soln., 2× daily
α/β -Antagonists				
Carvedilol (59)	Coreg	Boehringer	Aryloxypropanolamine	13–50 mg/day
Labetalol (26)	Normodyne	Allen & Hanburys	Phenylethylamine	200–2400 mg/day
Agonist/Antagonists				
Dobutamine (27)	Dobutrex	Lilly	Phenylethylamine	2–20 μ g/kg/min, i.v.
Isoxsuprine (28)	Vasodilan	Philips	Arylpropanolamine	30–80 mg/day

^aNot all trade names are listed, particularly for drugs no longer under patent.

^bAll dose information from *Drug Facts and Comparisons 2002* (14).

^cNot all doses and dosage forms are listed. For further information consult reference (14).

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.